Advancing Enobosarm, An Oral Novel Selective Androgen Receptor Modulator (SARM), to Avoid Muscle Loss and Augment Fat Loss When Combined with a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Drugs for Potentially Higher Quality Weight Loss
Time: 9:00 am
day: Conference Day Two
Details:
- Highlighting the concerns that muscle loss caused by GLP-1 receptor agonists may be responsible for weight loss plateau, upon stopping GLP-1 RA, the fat and weight rebound regain, and may accelerate the development of frailty in at-risk older sarcopenic obese patients with potential for physical function limitations
- Presenting the 5 clinical studies of enobosarm in older patients and in patients with a cancer induced starvation-like state that provide strong scientific rationale for ongoing Phase 2b enobosarm + GLP-1 RA clinical study
- Supporting evidence that enobosarm in combination with a GLP-1 RA may potentially augment the fat reduction with higher quality total weight loss while preserving muscle and physical function
